Education
About Us
Working with TipRanks
Follow Us
Avadel Pharmaceuticals (AVDL)
NASDAQ:AVDL
AVDL Stock Chart & Stats
$21.55
-$0.16(-1.47%)
At close: 4:00 PM EST
$21.55
-$0.16(-1.47%)
Day’s Range― - ―
52-Week Range$6.38 - $23.57
Previous CloseN/A
Volume358.54K
Average Volume (3M)1.87M
Market Cap
$2.11B
Enterprise Value$1.49B
Total Cash (Recent Filing)$91.58M
Total Debt (Recent Filing)$37.38M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Mar 09, 2026EPS Estimate
0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding97,817,590
10 Day Avg. Volume1,216,125
30 Day Avg. Volume1,869,954
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)13.54
Price to Sales (P/S)5.91
P/FCF Ratio-21.32
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue6.00
Enterprise Value/Gross Profit6.36
Enterprise Value/Ebitda147.31
Forecast
1Y Price Target
$20.29Price Target Upside-5.85% Downside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)0.19
Revenue Forecast (FY)$274.35M
Bulls Say, Bears Say
Bulls Say
Acquisition BenefitsThe acquisition is intended to immediately advance Alkermes into the sleep space by bringing in Avadel’s commercial product LUMRYZ, and leveraging Avadel’s commercial infrastructure and experience in the sleep business.
Earnings PotentialLumryz was previously guided to reach $265-275M, but recent sales estimates imply $280M+ of sales for the year, indicating potential for higher revenue.
Product Approval And ExpansionA new salt-free version of Lumryz could be approved in narcolepsy/IH by 2028, expanding the product's market potential.
Bears Say
Clinical Profile ConcernsLumryz's differentiated PK profile may not translate into IH the same as narcolepsy and the multiple oxybate salts in the Xywav may also have played a role in its clinical profile in IH.
Market CompetitionThe looming advent of sodium oxybate generics next year may also pressure pricing in the oxybate class.
Offer EvaluationLundbeck decided not to raise its offer, and its CVR payouts were considered unlikely to be achieved.
Avadel Pharmaceuticals News
AVDL FAQ
What was Avadel Pharmaceuticals’s price range in the past 12 months?
Avadel Pharmaceuticals lowest stock price was $6.38 and its highest was $23.57 in the past 12 months.
What is Avadel Pharmaceuticals’s market cap?
Avadel Pharmaceuticals’s market cap is $2.11B.
When is Avadel Pharmaceuticals’s upcoming earnings report date?
Avadel Pharmaceuticals’s upcoming earnings report date is Mar 09, 2026 which is in 69 days.
How were Avadel Pharmaceuticals’s earnings last quarter?
Avadel Pharmaceuticals released its earnings results on Nov 04, 2025. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.059 by -$0.059.
Is Avadel Pharmaceuticals overvalued?
According to Wall Street analysts Avadel Pharmaceuticals’s price is currently Overvalued.
Does Avadel Pharmaceuticals pay dividends?
Avadel Pharmaceuticals does not currently pay dividends.
What is Avadel Pharmaceuticals’s EPS estimate?
Avadel Pharmaceuticals’s EPS estimate is 0.1.
How many shares outstanding does Avadel Pharmaceuticals have?
Avadel Pharmaceuticals has 97,817,590 shares outstanding.
What happened to Avadel Pharmaceuticals’s price movement after its last earnings report?
Avadel Pharmaceuticals reported an EPS of $0 in its last earnings report, missing expectations of $0.059. Following the earnings report the stock price went up 0.317%.
Which hedge fund is a major shareholder of Avadel Pharmaceuticals?
Currently, no hedge funds are holding shares in AVDL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Avadel Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$20.29 (-5.85% Downside)
$20.29 (-5.85% Downside)
Blogger Sentiment
Bullish
AVDL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 21.0%
Last 30 Days ▼ 21.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
103.48%
12-Months-Change
Fundamentals
Return on Equity
-0.32%
Trailing 12-Months
Asset Growth
26.03%
Trailing 12-Months
Company Description
Avadel Pharmaceuticals
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
AVDL Company Deck
AVDL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with significant growth in patient demand, strong financial performance, and successful litigation outcomes. Although there are some concerns regarding pending royalty determinations and increased operating expenses, the positive aspects significantly outweigh the lowlights, indicating a strong position for future growth.View all AVDL earnings summariesAVDL Stock 12 Month Forecast
Average Price Target
$20.29
▼(-5.85% Downside)
Technical Analysis
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Evotec AG
―
Harrow Health
―
Ownership Overview
1.06% Insiders
12.24% Mutual Funds
36.27% Other Institutional Investors
39.26% Public Companies and Individual Investors